New dimensions in the treatment of muscle spasticity after stroke and nervous system defects

(Eötvös Loránd University (ELTE), Faculty of Science) Chronic muscle spasticity after nervous system defects like stroke, traumatic brain and spinal cord injury, multiple sclerosis and painful low back pain affect more than 10% of the population, with a socioeconomic cost of about 500 billion USD. Currently, there is no satisfying remedy to help these suffering people, which generates an immense medical need for a new generation antispastic drug. Drug candidate MPH-220 could mean new hope for...